Novo Nordisk’s ‘lottery ticket’: can obesity drugs help treat Alzheimer’s?
Results are due soon from two studies using semaglutide to treat thousands of people with the disease
Related reading
Novo Nordisk shares slump after drug failure in Alzheimer’s trial
Outcome is blow to one of Europe’s largest listed companies
Triple dose of Novo Nordisk drug delivers 19% weight loss in trials
Danish pharma group seeks to broaden options and stay competitive with Eli Lilly
New Novo Nordisk drug could beat market leaders for weight loss, early results…
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose
Novo Nordisk loses further ground in obesity market
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Novo Nordisk shares drop 15% after poor trial results for new obesity drug
Once-a-week injection achieved less weight loss than rival treatment
New Novo drug delivers significant weight-loss benefits in diabetes trial
Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline